IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos

Mitsuru Furukawa, Hironari Takaishi, Jiro Takito, Masaki Yoda, Sadaoki Sakai, Tomohiro Hikata, Akihiro Hakozaki, Shinichi Uchikawa, Morio Matsumoto, Kazuhiro Chiba, Tokuhiro Kimura, Yasunori Okada, Koichi Matsuo, Hiroki Yoshida, Yoshiaki Toyama

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

IL-27 was first discovered as a factor supporting initial Th1 immune responses. Subsequent studies revealed that this cytokine has pleiotropic effects, including inhibition of certain immune cells, a regulatory role in hemopoietic stem cell differentiation, and antitumor activities. However, the role of human IL (hIL)-27 in human osteoclast precursors and inflammatory bone disease is unclear. Here, we examined the direct effect of hIL-27 on human osteoclastogenesis. Human bone marrow cells cultured in MethoCult medium containing human (h) GM-CSF, human stem cell factor, and hIL-3 expressed Mac-1, c-kit, and c-Fms. These cells, called hCFU-GMs, also expressed the IL-27 receptor, an IL-27Rα (WSX-1)/gp130 heterodimer. Cultivation in hM-CSF and human receptor activator of NF-κB ligand induced the differentiation of tartrate-resistant acid phosphatase-positive multinucleated cells (osteoclasts) from hCFU-GMs, and hIL-27 inhibited this osteoclastogenesis in a dose-dependent manner. hIL-27 also repressed bone resorption by osteoclasts on a dentine slice. hIL-27 caused a remarkable increase in STAT1 phosphorylation and enhanced the STAT1 protein level. It also inhibited the expression of receptor activator of NF-κB ligand-induced c-Fos and cytoplasmic, calcineurin-dependent 1 NFAT (NFATc1), which are indispensable transcription factors for osteoclastogenesis. Fludarabine, a STAT1 inhibitor, and STAT1 small interfering RNA partially rescued the inhibition of osteoclastogenesis by IL-27. A WSX-1 deficiency caused severe inflammatory bone destruction primed by Escherichia coli cell wall lysate in vivo. Therefore, hIL-27 may act as an anti-inflammatory cytokine in human bone destruction, by inhibiting osteoclastogenesis from hCFU-GMs via STAT1-dependent down-regulation of the transcription factor c-Fos. Our results suggest that hIL-27 may prove useful as a therapeutic target for inflammatory bone destruction.

Original languageEnglish
Pages (from-to)2397-2406
Number of pages10
JournalJournal of Immunology
Volume183
Issue number4
DOIs
Publication statusPublished - 2009 Aug 15

Fingerprint

Interleukin-27
Granulocyte-Macrophage Progenitor Cells
Osteogenesis
Ligands
Osteoclasts
Bone and Bones
Transcription Factors
Colony-Stimulating Factor Receptors
STAT1 Transcription Factor
Cytokines
Stem Cell Factor
Calcineurin

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. / Furukawa, Mitsuru; Takaishi, Hironari; Takito, Jiro; Yoda, Masaki; Sakai, Sadaoki; Hikata, Tomohiro; Hakozaki, Akihiro; Uchikawa, Shinichi; Matsumoto, Morio; Chiba, Kazuhiro; Kimura, Tokuhiro; Okada, Yasunori; Matsuo, Koichi; Yoshida, Hiroki; Toyama, Yoshiaki.

In: Journal of Immunology, Vol. 183, No. 4, 15.08.2009, p. 2397-2406.

Research output: Contribution to journalArticle

Furukawa, M, Takaishi, H, Takito, J, Yoda, M, Sakai, S, Hikata, T, Hakozaki, A, Uchikawa, S, Matsumoto, M, Chiba, K, Kimura, T, Okada, Y, Matsuo, K, Yoshida, H & Toyama, Y 2009, 'IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos', Journal of Immunology, vol. 183, no. 4, pp. 2397-2406. https://doi.org/10.4049/jimmunol.0802091
Furukawa, Mitsuru ; Takaishi, Hironari ; Takito, Jiro ; Yoda, Masaki ; Sakai, Sadaoki ; Hikata, Tomohiro ; Hakozaki, Akihiro ; Uchikawa, Shinichi ; Matsumoto, Morio ; Chiba, Kazuhiro ; Kimura, Tokuhiro ; Okada, Yasunori ; Matsuo, Koichi ; Yoshida, Hiroki ; Toyama, Yoshiaki. / IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. In: Journal of Immunology. 2009 ; Vol. 183, No. 4. pp. 2397-2406.
@article{91211a03d1d24efb8c6fc944b03f0d52,
title = "IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos",
abstract = "IL-27 was first discovered as a factor supporting initial Th1 immune responses. Subsequent studies revealed that this cytokine has pleiotropic effects, including inhibition of certain immune cells, a regulatory role in hemopoietic stem cell differentiation, and antitumor activities. However, the role of human IL (hIL)-27 in human osteoclast precursors and inflammatory bone disease is unclear. Here, we examined the direct effect of hIL-27 on human osteoclastogenesis. Human bone marrow cells cultured in MethoCult medium containing human (h) GM-CSF, human stem cell factor, and hIL-3 expressed Mac-1, c-kit, and c-Fms. These cells, called hCFU-GMs, also expressed the IL-27 receptor, an IL-27Rα (WSX-1)/gp130 heterodimer. Cultivation in hM-CSF and human receptor activator of NF-κB ligand induced the differentiation of tartrate-resistant acid phosphatase-positive multinucleated cells (osteoclasts) from hCFU-GMs, and hIL-27 inhibited this osteoclastogenesis in a dose-dependent manner. hIL-27 also repressed bone resorption by osteoclasts on a dentine slice. hIL-27 caused a remarkable increase in STAT1 phosphorylation and enhanced the STAT1 protein level. It also inhibited the expression of receptor activator of NF-κB ligand-induced c-Fos and cytoplasmic, calcineurin-dependent 1 NFAT (NFATc1), which are indispensable transcription factors for osteoclastogenesis. Fludarabine, a STAT1 inhibitor, and STAT1 small interfering RNA partially rescued the inhibition of osteoclastogenesis by IL-27. A WSX-1 deficiency caused severe inflammatory bone destruction primed by Escherichia coli cell wall lysate in vivo. Therefore, hIL-27 may act as an anti-inflammatory cytokine in human bone destruction, by inhibiting osteoclastogenesis from hCFU-GMs via STAT1-dependent down-regulation of the transcription factor c-Fos. Our results suggest that hIL-27 may prove useful as a therapeutic target for inflammatory bone destruction.",
author = "Mitsuru Furukawa and Hironari Takaishi and Jiro Takito and Masaki Yoda and Sadaoki Sakai and Tomohiro Hikata and Akihiro Hakozaki and Shinichi Uchikawa and Morio Matsumoto and Kazuhiro Chiba and Tokuhiro Kimura and Yasunori Okada and Koichi Matsuo and Hiroki Yoshida and Yoshiaki Toyama",
year = "2009",
month = "8",
day = "15",
doi = "10.4049/jimmunol.0802091",
language = "English",
volume = "183",
pages = "2397--2406",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - IL-27 abrogates receptor activator of NF-κB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos

AU - Furukawa, Mitsuru

AU - Takaishi, Hironari

AU - Takito, Jiro

AU - Yoda, Masaki

AU - Sakai, Sadaoki

AU - Hikata, Tomohiro

AU - Hakozaki, Akihiro

AU - Uchikawa, Shinichi

AU - Matsumoto, Morio

AU - Chiba, Kazuhiro

AU - Kimura, Tokuhiro

AU - Okada, Yasunori

AU - Matsuo, Koichi

AU - Yoshida, Hiroki

AU - Toyama, Yoshiaki

PY - 2009/8/15

Y1 - 2009/8/15

N2 - IL-27 was first discovered as a factor supporting initial Th1 immune responses. Subsequent studies revealed that this cytokine has pleiotropic effects, including inhibition of certain immune cells, a regulatory role in hemopoietic stem cell differentiation, and antitumor activities. However, the role of human IL (hIL)-27 in human osteoclast precursors and inflammatory bone disease is unclear. Here, we examined the direct effect of hIL-27 on human osteoclastogenesis. Human bone marrow cells cultured in MethoCult medium containing human (h) GM-CSF, human stem cell factor, and hIL-3 expressed Mac-1, c-kit, and c-Fms. These cells, called hCFU-GMs, also expressed the IL-27 receptor, an IL-27Rα (WSX-1)/gp130 heterodimer. Cultivation in hM-CSF and human receptor activator of NF-κB ligand induced the differentiation of tartrate-resistant acid phosphatase-positive multinucleated cells (osteoclasts) from hCFU-GMs, and hIL-27 inhibited this osteoclastogenesis in a dose-dependent manner. hIL-27 also repressed bone resorption by osteoclasts on a dentine slice. hIL-27 caused a remarkable increase in STAT1 phosphorylation and enhanced the STAT1 protein level. It also inhibited the expression of receptor activator of NF-κB ligand-induced c-Fos and cytoplasmic, calcineurin-dependent 1 NFAT (NFATc1), which are indispensable transcription factors for osteoclastogenesis. Fludarabine, a STAT1 inhibitor, and STAT1 small interfering RNA partially rescued the inhibition of osteoclastogenesis by IL-27. A WSX-1 deficiency caused severe inflammatory bone destruction primed by Escherichia coli cell wall lysate in vivo. Therefore, hIL-27 may act as an anti-inflammatory cytokine in human bone destruction, by inhibiting osteoclastogenesis from hCFU-GMs via STAT1-dependent down-regulation of the transcription factor c-Fos. Our results suggest that hIL-27 may prove useful as a therapeutic target for inflammatory bone destruction.

AB - IL-27 was first discovered as a factor supporting initial Th1 immune responses. Subsequent studies revealed that this cytokine has pleiotropic effects, including inhibition of certain immune cells, a regulatory role in hemopoietic stem cell differentiation, and antitumor activities. However, the role of human IL (hIL)-27 in human osteoclast precursors and inflammatory bone disease is unclear. Here, we examined the direct effect of hIL-27 on human osteoclastogenesis. Human bone marrow cells cultured in MethoCult medium containing human (h) GM-CSF, human stem cell factor, and hIL-3 expressed Mac-1, c-kit, and c-Fms. These cells, called hCFU-GMs, also expressed the IL-27 receptor, an IL-27Rα (WSX-1)/gp130 heterodimer. Cultivation in hM-CSF and human receptor activator of NF-κB ligand induced the differentiation of tartrate-resistant acid phosphatase-positive multinucleated cells (osteoclasts) from hCFU-GMs, and hIL-27 inhibited this osteoclastogenesis in a dose-dependent manner. hIL-27 also repressed bone resorption by osteoclasts on a dentine slice. hIL-27 caused a remarkable increase in STAT1 phosphorylation and enhanced the STAT1 protein level. It also inhibited the expression of receptor activator of NF-κB ligand-induced c-Fos and cytoplasmic, calcineurin-dependent 1 NFAT (NFATc1), which are indispensable transcription factors for osteoclastogenesis. Fludarabine, a STAT1 inhibitor, and STAT1 small interfering RNA partially rescued the inhibition of osteoclastogenesis by IL-27. A WSX-1 deficiency caused severe inflammatory bone destruction primed by Escherichia coli cell wall lysate in vivo. Therefore, hIL-27 may act as an anti-inflammatory cytokine in human bone destruction, by inhibiting osteoclastogenesis from hCFU-GMs via STAT1-dependent down-regulation of the transcription factor c-Fos. Our results suggest that hIL-27 may prove useful as a therapeutic target for inflammatory bone destruction.

UR - http://www.scopus.com/inward/record.url?scp=70149083341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149083341&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0802091

DO - 10.4049/jimmunol.0802091

M3 - Article

VL - 183

SP - 2397

EP - 2406

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -